Viatris Inc. logo
Viatris Inc. (VTRS)
Compare

Viatris Inc. (VTRS) SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

FormFiling DateAcceptedDocument
8-KJun 18, 2026Jun 18, 2026View filing
8-KJun 15, 2026Jun 15, 2026View filing
424B5Jun 15, 2026Jun 15, 2026View filing
FWPJun 12, 2026Jun 12, 2026View filing
424B5Jun 12, 2026Jun 12, 2026View filing
8-KMay 15, 2026May 15, 2026View filing
10-QMay 7, 2026May 7, 2026View filing
8-KMay 7, 2026May 7, 2026View filing
SC 13G/AMay 5, 2026May 5, 2026View filing
8-KMay 4, 2026May 4, 2026View filing
SC 13GApr 30, 2026Apr 30, 2026View filing
4Apr 16, 2026Apr 16, 2026View filing
ARSApr 2, 2026Apr 2, 2026View filing
DEFA14AApr 2, 2026Apr 2, 2026View filing
DEF 14AApr 2, 2026Apr 2, 2026View filing
SC 13G/AMar 27, 2026Mar 27, 2026View filing
4Mar 24, 2026Mar 24, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing
4Mar 10, 2026Mar 10, 2026View filing

About Viatris Inc.

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Canonsburg, PA
32,000 employees
Healthcare / Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Scott Andrew Smith